|Mr. Nikolaj Sorensen||President & CEO||5.78M||N/A||1972|
|Mr. Fredrik Jarrsten||Executive VP & CFO||N/A||N/A||1967|
|Ms. Cecilia Coupland||Senior VP & Head of Operations||N/A||N/A||1976|
|Lena Wange||Investor Relations & Communications Director||N/A||N/A||N/A|
|Mr. Robert Ronn||Senior VP and Head of R&D||N/A||N/A||1976|
|Dr. Edward Kim M.B.A., M.D.||Chief Medical Officer||N/A||N/A||N/A|
|Mr. Robert A. Deluca||President of Orexo US Inc||N/A||N/A||1961|
|Mr. Jesper Lind||Advisor||N/A||N/A||1960|
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is also developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 for emergency treatment of allergic reactions; and OX-MPI for the treatment of endometriosis. In addition, its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.
Orexo AB (publ)’s ISS governance QualityScore as of 1 December 2023 is 5. The pillar scores are Audit: 8; Board: 1; Shareholder rights: 4; Compensation: 10.